Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up to 75 percent for people living with diabetes starting in January 2024.
"We have been working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes," said Steve Albers, senior vice president of market access and public affairs at Novo Nordisk, Inc. "Novo Nordisk remains committed to ensuring patients living with diabetes can afford our insulins, a responsibility we take seriously."
Earlier this month, rival drugmaker Eli Lilly announced plans to reduce insulin prices by 70 percent and cap patient out-of-pocket costs for insulin at $35 per month.
The Biden administration has put public pressure on drugmakers to make medically necessary insulins more affordable. Novo Nordisk notably did not put a cap on out-of-pocket expenses.
Novo Nordisk will lower the price for four different brands, including NovoLog® and NovoLog® Mix 70/30 by 75 percent and Novolin® and Levemir® by 65 percent.
Cheddar News checks in to see what to look out for on The Day Ahead as Campbell Soup and Vera Bradley are due to report earnings while economic data, including the April trade deficit and consumer credit, are slated to be released. And Wednesday is World Food Safety Day.
Financial services company Marqeta released its fourth annual state of payments report which reveals how widely Americans have adopted new technology like mobile banking and wallets. Marqeta CEO Simon Khalaf joined Cheddar News to discuss how common digital payments have become.
Katherine Rooney Vera, chief market strategist with StoneX, joined Cheddar News to discuss what investors should expect as the S&P closed near a nine-month high with volatility levels at their lowest level in over three years.
